Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04179500
Other study ID # Pa-824-CL-012
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date September 16, 2021
Est. completion date August 30, 2024

Study information

Verified date September 2023
Source Global Alliance for TB Drug Development
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pretomanid is being used in an antimicrobial combination regimen(s) to treat patients with pulmonary tuberculosis (TB). The primary purpose of the Male Reproductive Safety - "BPaMZ/SEM"- clinical study is to evaluate the potential effect of pretomanid on human testicular function whilst being used in a 26 weeks antimicrobial combination regimen consisting of bedaquiline (B) plus pretomanid (Pa) plus moxifloxacin (M) and pyrazinamide (Z) (BPaMZ).


Description:

The primary objective of this study is to assess the male reproductive safety of pretomanid in the regimen (BPaMZ) of bedaquiline 200mg (200mg daily for 8 weeks then 100 mg daily for 18 weeks), together with pretomanid 200 mg (1x daily) + moxifloxacin 400 mg (1x daily) + pyrazinamide 1500 mg (1 x daily) for 26 weeks in participants with drug-resistant pulmonary tuberculosis (DR-TB). The secondary objective of the study is to evaluate the tuberculosis (TB) treatment efficacy, safety and tolerability after 26 weeks of active treatment for TB and follow up until 52 weeks after end of the above-described treatment regimen in participants with DR-TB.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 26
Est. completion date August 30, 2024
Est. primary completion date June 19, 2023
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Understands study procedures and voluntarily provides written informed consent prior to the start of any study-specific procedures. 2. Male gender 18 years or over 3. Body weight (in light clothing and no shoes) = 45kg. 4. A positive molecular test for tuberculosis in sputum either at screening or within one month prior to enrolment. 5. Disease Characteristics: - Participants must have been diagnosed with TB prior to or at screening - Participants' TB should be resistant to rifampicin and/or isoniazid, and susceptible to fluoroquinolones by rapid sputum-based tests. - Participants who have had previous treatment for DR-TB for more than 3 months at start of screening should be discussed with the medical monitor. 6. A chest x-ray, within 26 weeks prior to or at the screening visit, which in the opinion of the Investigator is compatible with pulmonary TB Exclusion criteria: 1. Resistant to fluoroquinolones by rapid molecular test 2. History of male infertility or vasectomy 3. Unable to produce semen sample 4. Evidence at screening of azoospermia 5. Known erectile dysfunction that would prevent ejaculation. 6. Historical or active disease process of the male reproductive tract that would compromise sperm production. e.g. tuberculous epididymitis. 7. History of any illness that, in the opinion of the Investigator, might confound the results of the study or poses an additional risk to the participant by their participation in the study. 8. For HIV infected participants any of the following: 1. CD4+ count <100 cells/µL 2. Received intravenous antifungal medication within the last 90 days 9. Participants with newly diagnosed tuberculosis and HIV that require initiation of appropriate HIV therapy before participants has received at least 2 weeks of an antituberculosis regimen. 10. Received pretomanid and/or delamanid to treat TB 11. Known chronic hepatitis B or C 12. For HIV infected participants: 1. The following antiretroviral therapy (ART) should not be used: 1. Stavudine 2. Zidovudine 3. Didanosine 4. Triple NRTI regimen is not considered optimal for HIV treatment (poor efficacy) 13. Participants with the following toxicities at screening as defined by the enhanced Division of Microbiology and Infectious Disease (DMID) adult toxicity table (Draft November 2007) where applicable: 1. Platelets <75,000/mm3 2. Creatinine >1.5 times upper limit of normal (ULN) 3. eGFR = 60 mL/min 4. Haemoglobin <8.0 g/dL 5. Serum potassium less than the lower limit of normal for the laboratory. This may be repeated once 6. AST: - =3.0 x ULN to be excluded - results between 1.5 x ULN and 3 x ULN must be discussed with and approved by the Sponsor Medical Monitor 7. ALT: - =3.0 x ULN to be excluded - greater than ULN must be discussed with and approved by the Sponsor Medical Monitor 8. ALP: - =3.0 x ULN to be excluded - 2.0 - <3.0 x ULN must be discussed with and approved by the Sponsor Medical Monitor 9. Total bilirubin: - >1.5 x ULN to be excluded - Greater than ULN must be discussed with and approved by the Sponsor Medical Monitor 10. Direct bilirubin: • greater than 1x ULN to be excluded 11. Positive hepatitis B surface Ag, or hepatitis C antibody

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Pretomanid
pretomanid 200 mg (once daily) for 26 weeks (with meal)
Bedaquiline
bedaquiline 200 mg (once daily) for 8 weeks (with meal), then bedaquiline 100mg (once daily) for 18 weeks (with meal)
moxifloxacin
moxifloxacin 400 mg (once daily) for 26 weeks (with meal)
pyrazinamide
pyrazinamide 1500 mg (once daily) for 26 weeks (with meal)

Locations

Country Name City State
Georgia National Center for Tuberculosis and Lung Diseases Tbilisi
South Africa CHRU, Sizwe Tropical Diseases Hospital Johannesburg
South Africa Isango Lethemba TB Research Unit Empilweni TB Hospital Port Elizabeth
South Africa The Aurum Institute: Rustenburg Clinical Research Centre Rustenburg

Sponsors (1)

Lead Sponsor Collaborator
Global Alliance for TB Drug Development

Countries where clinical trial is conducted

Georgia,  South Africa, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total Sperm Number - Week 26 Change from baseline in total sperm number at 26 weeks of therapy. Week 26
Secondary Total Sperm Number - Week 13 and Week 44 Change from baseline in total sperm number at 13 weeks of therapy and at 18 weeks post end of therapy. Week 13 to Week 44
Secondary Change in Male Reproductive Hormones The change from baseline in Male reproductive hormones at Week 2, 4, 8, 12, 16, 35, 44, 52, 65, 78 and at early withdrawal. Reproductive hormones: luteinizing hormone (LH), follicle-stimulating hormone (FSH), Inhibin B and Testosterone. Up to Week 78
See also
  Status Clinical Trial Phase
Recruiting NCT05738681 - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT05526885 - Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa N/A
Completed NCT04369326 - Community Initiated Preventive Therapy for TB N/A
Recruiting NCT04568967 - TB-CAPT EXULTANT - HIV N/A
Completed NCT02337270 - Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol Phase 1
Not yet recruiting NCT06253715 - Shortened Regimen for Drug-susceptible TB in Children Phase 3
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Withdrawn NCT03639038 - Tuberculosis Diagnosis by Flow Cytometry
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Recruiting NCT04975178 - Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa Phase 3
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03973970 - Assessing the Ability of the T-SPOT®.TB Test (IQ)
Recruiting NCT04230395 - Alcohol Reduction Among People With TB and HIV in India N/A
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Active, not recruiting NCT02906007 - Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV Phase 1/Phase 2
Not yet recruiting NCT05917210 - Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda N/A
Not yet recruiting NCT06017843 - Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding N/A
Not yet recruiting NCT05845112 - Start Taking Action For TB Diagnosis
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Completed NCT02781909 - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis Phase 2